Evidence map›Paper›PMID 41988191›Full record

ArticleFrontiers in immunology2026

Discovering novel therapeutic V

Autumn T LaPointe, Fortunato Ferrara, Jennifer M Zupancic, Alba L Montoya, Jurgen Schmidt, Li-Wei Hung, Alison M Kell, Nileena Velappan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Autumn T LaPointeDepartment of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM, United States.
Fortunato FerraraSpecifica Inc. an IQVIA company, Santa Fe, NM, United States.
Jennifer M ZupancicBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States.
Alba L MontoyaBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States.
Jurgen SchmidtBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States.
Li-Wei HungBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States.
Alison M KellDepartment of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM, United States.
Nileena VelappanBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Evolution or emergence of a new viral variant is a significant public health concern. Alphaviruses, such as Venezuelan equine encephalitis virus (VEEV), are mosquito-borne viruses which are becoming more prevalent due to expansion of vector habitats. Despite this, there are currently no antiviral therapies or FDA-approved vaccines available to treat or prevent VEEV infection. The increased prevalence of such viruses provides opportunities for novel variants to evolve. Key therapeutic molecules that could be developed against viral pathogens are recombinant antibodies or antibody fragments, such as the variable heavy domain of heavy chain antibodies (V Methods: Results: Here we report four novel "human" V Discussion: Though non-neutralizing, these V

Indexed as

Antibodies, ViralEncephalitis Virus, Venezuelan EquineImmunoglobulin Heavy ChainsAnimalsHumansPeptide LibraryViral Envelope ProteinsAntibodies, ViralImmunoglobulin Heavy ChainsPeptide LibraryViral Envelope Proteinsantigen designemerging virusesnanobodynon-neutralizing antibodiespeptide synthesisphage and yeast display

Identifiers

PMID41988191
PMCPMC13076302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.